BACKGROUND: The Swedish Family-Cancer Database (FCD) is the largest source of data on familial cancer in the world, including practically complete family structures and individual cancer diagnoses from the high-quality cancer registry. We present a novel application of FCD by analyzing age-specific familial risks and interpreting them through likely causes, such as germline pathogenic variants and/or environmental exposures. MAIN BODY: The basic assumption for this approach is that a discrete familial clustering in a narrow age-interval is not random but may provide causal clues. For this analysis we selected reasonably common cancers to meaningfully scrutinize familial risk through adulthood in which cancers are diagnosed, that included colorectal (CRC) and endometrial cancers, prostate and kidney cancers and breast and lung cancers. The interpretation is based on the literature. The highest familial relative risks for CRC and endometrial cancers were found at ages 40-44 years, matching the peak impact of mismatch repair gene mutations. However endometrial cancer showed also a small early onset component which could not be explained. Age-related familial risks for breast, prostate and kidney cancers also matched data from large-scale sequencing; these included the early onset component in kidney cancer which was likely due to VHL mutations. Age distribution of familial lung cancer was unique in showing a wide peak extending from middle to old ages, which would be consistent with a combination of direct genetic effects and indirect influence on inheritance of smoking dependence. CONCLUSIONS: The present review of age-specific familial risks and age-of-onset data from the literature may allow an interpretation that the familial and germline landscapes are reasonably harmonious for relatively early onset cancers but at higher ages no discrete peaks can be found which may implicate attenuated impact of high-risk genes and polygenic influence.

Biomedical Center Faculty of Medicine Charles University Pilsen 30605 Czech Republic

Cancer Consortium Heidelberg Germany

Cancer Gene Therapy Group Translational Immunology Research Program University of Helsinki Helsinki Finland

Comprehensive Cancer Center Helsinki University Hospital Helsinki Finland

Department of Urology Helsinki University Hospital Helsinki Finland

Division of Cancer Epidemiology German Cancer Research Center Im Neuenheimer Feld 580 Heidelberg 69120 Germany

Division of Pediatric Neurooncology German Cancer Research Center Heidelberg Germany

Hopp Children's Cancer Center Heidelberg Germany

Hunter Medical Research Institute New Lambton NSW Australia

The University of Newcastle Callaghan NSW Australia

Zobrazit více v PubMed

Weires M, Bermejo JL, Sundquist J, Hemminki K. Clustering of concordant and discordant cancer types in Swedish couples is rare. Eur J Cancer. 2011;47:98–106. PubMed

Czene K, Lichtenstein P, Hemminki K. Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish family-cancer database. Int J Cancer. 2002;99:260–6. PubMed

Lichtenstein P, Holm N, Verkasalo P, Illiado A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer. N Engl J Med. 2000;343:78–85. PubMed

Hemminki K, Sundquist K, Sundquist J, Försti A, Hemminki A, Li X. Familial risks and proportions describing population landscape of familial cancer. Cancers. 2021;13(17):4385. PubMed PMC

Hemminki K, Li X, Försti A, Eng C. Are population level familial risks and germline genetics meeting each other? Hered Cancer Clin Pract. 2023;21(1):3. PubMed PMC

Chubb D, Broderick P, Frampton M, Kinnersley B, Sherborne A, Penegar S, et al. Genetic diagnosis of high-penetrance susceptibility for colorectal cancer (CRC) is achievable for a high proportion of familial CRC by exome sequencing. J Clin Oncol. 2015;33(5):426–32. PubMed

Dominguez-Valentin M, Sampson JR, Seppälä TT, Ten Broeke SW, Plazzer JP, Nakken S, et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med. 2020;22(1):15–25. PubMed PMC

Møller P, Seppälä TT, Bernstein I, Holinski-Feder E, Sala P, Gareth Evans D, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut. 2018;67(7):1306–16. PubMed PMC

Thomas M, Su YR, Rosenthal EA, Sakoda LC, Schmit SL, Timofeeva MN, et al. Combining Asian and European genome-wide association studies of colorectal cancer improves risk prediction across racial and ethnic populations. Nat Commun. 2023;14(1):6147. PubMed PMC

Vietri MT, D’Elia G, Caliendo G, Casamassimi A, Federico A, Passariello L, et al. Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer. Med Oncol. 2021;38(2):13. PubMed PMC

Dörk T, Hillemanns P, Tempfer C, Breu J, Fleisch MC. Genetic susceptibility to endometrial cancer: risk factors and clinical management. Cancers. 2020;12(9):2407. PubMed PMC

Kral J, Jelinkova S, Zemankova P, Vocka M, Borecka M, Cerna L, et al. Germline multigene panel testing of patients with endometrial cancer. Oncol Lett. 2023;25(6):216. PubMed PMC

Cummings S, Alfonso A, Hughes E, Kucera M, Mabey B, Singh N, et al. Cancer risk associated with PTEN pathogenic variants identified using multigene hereditary cancer panel testing. JCO Precis Oncol. 2023;7:e2200415. PubMed PMC

Tzortzatos G, Aravidis C, Lindblom A, Mints M, Tham E. Screening for germline phosphatase and tensin homolog-mutations in suspected Cowden syndrome and Cowden syndrome-like families among uterine cancer patients. Oncol Lett. 2015;9(4):1782–6. PubMed PMC

Chung JH, Dewal N, Sokol E, Mathew P, Whitehead R, Millis SZ, et al. Prospective comprehensive genomic profiling of primary and metastatic prostate tumors. JCO Precis Oncol. 2019;3:PO.18.00283. PubMed PMC

Pritzlaff M, Tian Y, Reineke P, Stuenkel AJ, Allen K, Gutierrez S, et al. Diagnosing hereditary cancer predisposition in men with prostate cancer. Genet Med. 2020;22(9):1517–23. PubMed PMC

Paulo P, Cardoso M, Brandão A, Pinto P, Falconi A, Pinheiro M, et al. Genetic landscape of homologous recombination repair genes in early-onset/familial prostate cancer patients. Genes Chromosomes Cancer. 2023;62(12):710–20. PubMed

Liu H, Sundquist J, Hemminki K. Familial renal cell carcinoma from the Swedish family-cancer database. Eur Urol. 2011;60:987–93. PubMed

Yngvadottir B, Andreou A, Bassaganyas L, Larionov A, Cornish AJ, Chubb D, et al. Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases. Hum Mol Genet. 2022;31(17):3001–11. PubMed PMC

Hemminki K, Jiang Y, Ma X, Yang K, Egevad L, Lindblad P. Molecular epidemiology of VHL gene mutations in renal cell carcinoma patients: relation to dietary and other factors. Carcinogenesis. 2002;23(5):809–15. PubMed

Dorling L, Carvalho S, Allen J, González-Neira A, Luccarini C, Wahlström C, et al. Breast cancer risk genes - association analysis in more than 113,000 women. N Engl J Med. 2021;384(5):428–39. PubMed PMC

Mavaddat N, Dorling L, Carvalho S, Allen J, González-Neira A, Keeman R, et al. Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes. JAMA Oncol. 2022;8(3):e216744. PubMed PMC

Xiao Q, Mao X, Ploner A, Grassmann F, Rodriguez J, Eriksson M, et al. Cancer risks among first-degree relatives of women with a genetic predisposition to breast cancer. J Natl Cancer Inst. 2024;116:911–9. PubMed PMC

Gronwald J, Cybulski C, Piesiak W, Suchy J, Huzarski T, Byrski T, et al. Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband. Br J Cancer. 2009;100(9):1508–12. PubMed PMC

Moslemi M, Vafaei M, Khani P, Soheili M, Nedaeinia R, Manian M, et al. The prevalence of ataxia telangiectasia mutated (ATM) variants in patients with breast cancer patients: a systematic review and meta-analysis. Cancer Cell Int. 2021;21(1):474. PubMed PMC

IARC. Personal habits and indoor combustions, vol. 100E. Lyon: International Agency for Research on Cancer; 2012. p. 575.

Tindle HA, Stevenson Duncan M, Greevy RA, Vasan RS, Kundu S, Massion PP, et al. Lifetime smoking history and risk of lung cancer: results from the Framingham heart study. J Natl Cancer Inst. 2018;110(11):1201–7. PubMed PMC

Tichanek F, Försti A, Hemminki O, Hemminki A, Hemminki K. Survival in lung cancer in the Nordic countries through a half century. Clin Epidemiol. 2023;15:503–10. PubMed PMC

Patja K, Hakala SM, Boström G, Nordgren P, Haglund M. Trends of tobacco use in Sweden and Finland: do differences in tobacco policy relate to tobacco use? Scand J Public Health. 2009;37(2):153–60. PubMed

Hemminki K, Försti A, Hemminki A, Ljungberg B, Hemminki O. Incidence trends in lung and bladder cancers in the Nordic Countries before and after the smoking epidemic. Eur J Cancer Prev. 2022;31(3):228–34. PubMed

Benusiglio PR, Fallet V, Sanchis-Borja M, Coulet F, Cadranel J. Lung cancer is also a hereditary disease. Eur Respir Rev. 2021;30(162):210045. PubMed PMC

Reckamp KL, Behrendt CE, Slavin TP, Gray SW, Castillo DK, Koczywas M, et al. Germline mutations and age at onset of lung adenocarcinoma. Cancer. 2021;127(15):2801–6. PubMed PMC

Wang Y, Broderick P, Matakidou A, Eisen T, Houlston RS. Chromosome 15q25 (CHRNA3-CHRNA5) variation impacts indirectly on lung cancer risk. PLoS One. 2011;6(4):e19085. PubMed PMC

Lorenzo Bermejo J, Hemminki K. Familial lung cancer and aggregation of smoking habits:a simulation of the effect of shared environmental factors on the familial risk of cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1738–40. PubMed

Weires MB, Tausch B, Haug PJ, Edwards CQ, Wetter T, Cannon-Albright LA. Familiality of diabetes mellitus. Exp Clin Endocrinol Diabetes. 2007;115:634–40. PubMed

Lubinski J, Kotsopoulos J, Moller P, Pal T, Eisen A, Peck L, et al. MRI surveillance and breast cancer mortality in women with BRCA1 and BRCA2 sequence variations. JAMA Oncol. 2024;10:493–9. PubMed PMC

Cybulski C, Zamani N, Kluźniak W, Milano L, Wokołorczyk D, Stempa K, et al. Variants in ATRIP are associated with breast cancer susceptibility in the Polish population and UK Biobank. Am J Hum Genet. 2023;110(4):648–62. PubMed PMC

Kharazmi E, Fallah M, Sundquist K, Hemminki K. Familial risk of early and late onset cancer: nationwide prospective cohort study. BMJ. 2012;345:e8076. PubMed PMC

Zhang YD, Hurson AN, Zhang H, Choudhury PP, Easton DF, Milne RL, et al. Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. Nat Commun. 2020;11(1):3353. PubMed PMC

Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919–32. PubMed

Blount J, Prakash A. The changing landscape of Lynch syndrome due to PMS2 mutations. Clin Genet. 2018;94(1):61–9. PubMed PMC

Brandt A, Bermejo JL, Sundquist J, Hemminki K. Age of onset in familial cancer. Ann Oncol. 2008;19:2084–8. PubMed PMC

Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, et al. Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2019;69(3):184–210. PubMed